BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Igata Y, Kudo M, Kojima M, Kami S, Aoki K, Satake T, Kobayashi T, Sugimoto M, Kobayashi S, Konishi M, Gotohda N. Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report. World J Clin Cases 2024; 12(34): 6721-6727 [PMID: 39650816 DOI: 10.12998/wjcc.v12.i34.6721]
URL: https://www.wjgnet.com/2307-8960/full/v12/i34/6721.htm
Number Citing Articles
1
Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu, Kenichiro Kato, Hiromichi Ito, Arisa Ueki, Takeshi Okamoto, Masato Ozaka, Yu Takahashi, Naoki Sasahira. Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiencyClinical Journal of Gastroenterology 2025; 18(3): 520 doi: 10.1007/s12328-025-02122-1
2
Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang. Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challengesWorld Journal of Gastroenterology 2025; 31(15): 104901 doi: 10.3748/wjg.v31.i15.104901